First Time Loading...
N

Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707

Watchlist Manager
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
Watchlist
Price: 13.7 CNY 5.14% Market Closed
Updated: May 5, 2024
Section:
 

Relative Value

The Relative Value of one Nanjing King-friend Biochemical Pharmaceutical Co Ltd stock under the Base Case scenario is 26.88 CNY. Compared to the current market price of 13.7 CNY, Nanjing King-friend Biochemical Pharmaceutical Co Ltd is Undervalued by 49%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
26.88 CNY
Undervaluation 49%
Relative Value
Price
N
Worst Case
Base Case
Best Case

Valuation Multiples

5.5
P/S
P/S
Price to Sales
5.5
vs History
85
vs Industry
24
Median 3Y
7.5
Median 5Y
7.5
Industry
2.5
Forward
5.2
More Details
21.6
P/E
P/E
Price to Earnings
21.6
vs History
82
vs Industry
24
Median 3Y
25.4
Median 5Y
27.3
Industry
23.4
Forward
19.7
More Details
19.5
P/OCF
P/OCF
Price to OCF
19.5
vs History
42
vs Industry
23
Median 3Y
27.5
Median 5Y
17.7
Industry
17.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
16
Median 3Y
-39.9
Median 5Y
-39.9
Industry
23.6
More Details
3.2
P/B
P/B
Price to Book Value
3.2
vs History
88
vs Industry
25
Median 3Y
4.8
Median 5Y
5.4
Industry
2.1
More Details
5.1
EV/S
EV/S
Enterprise Value to Sales
5.1
vs History
90
vs Industry
25
Median 3Y
8
Median 5Y
8
Industry
2.6
Forward
4.8
More Details
10.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
10.4
vs History
88
vs Industry
21
Median 3Y
14.7
Median 5Y
14.7
Industry
5.2
More Details
19.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
19.2
vs History
90
vs Industry
20
Median 3Y
25.5
Median 5Y
26.4
Industry
13.7
Forward
14
More Details
19.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
19.2
vs History
90
vs Industry
24
Median 3Y
25.5
Median 5Y
26.4
Industry
17.2
Forward
13.1
More Details
17.9
EV/OCF
EV/OCF
Enterprise Value to OCF
17.9
vs History
42
vs Industry
26
Median 3Y
29.1
Median 5Y
16.1
Industry
16.2
More Details
24.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
24.5
vs History
38
vs Industry
18
Median 3Y
53.8
Median 5Y
-22.7
Industry
17.8
More Details
3.4
EV/IC
EV/IC
Enterprise Value to IC
3.4
vs History
74
vs Industry
26
Median 3Y
3.8
Median 5Y
4
Industry
2
More Details

Multiples Across Competitors

Competitors Multiples
Nanjing King-friend Biochemical Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
22.1B CNY 5.5 21.6 19.2 19.2
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
698.5B USD 19.4 113.8 55.8 63.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.8T DKK 16.3 45.3 33.1 36.1
US
Johnson & Johnson
NYSE:JNJ
359.3B USD 4.2 9.3 11.5 15
US
Merck & Co Inc
NYSE:MRK
322.8B USD 5.3 140 33.3 52.8
UK
AstraZeneca PLC
LSE:AZN
186.8B GBP 5.1 39.3 140.7 225.6
CH
Novartis AG
SIX:NOVN
179.8B CHF 4.3 13.4 9.8 16.2
CH
Roche Holding AG
SIX:ROG
173.2B CHF 3 15.1 8.6 10.2
US
Pfizer Inc
NYSE:PFE
157B USD 2.9 -508.1 12.6 20.1

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 134,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.